Journal Article

DKFZ-2024-02163

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer.

Suarez-Carmona, M. (First author)DKFZ* ; Halama, N. (Last author)DKFZ*

2024
Elsevier Amsterdam

This record in other databases:

Please use a persistent id in citations: doi:10.1016/j.trecan.2024.10.006

Abstract: Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.

Keyword(s): MSI ; colorectal cancer ; dMMR ; immune checkpoint inhibition ; neoadjuvant therapy

Note: #EA:D196#LA:D196# / 2024 Dec;10(12):1093-1094 / HI-TRON / SPOTLIGHT

---

Contributing Institute(s):

1. Translationale Immuntherapie (D196)

Research Program(s):

1. 314 - Immunologie und Krebs (POF4-314) (POF4-314)

Appears in the scientific report 2024

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---